Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Mezzion Pharma Statistics

Total Valuation

Mezzion Pharma has a market cap or net worth of KRW 2.62 trillion. The enterprise value is 2.61 trillion.

Market Cap	2.62T
Enterprise Value	2.61T

Important Dates

The last earnings date was Friday, April 3, 2026.

Earnings Date	Apr 3, 2026
Ex-Dividend Date	n/a

Share Statistics

Mezzion Pharma has 30.38 million shares outstanding. The number of shares has increased by 0.95% in one year.

Current Share Class	30.38M
Shares Outstanding	30.38M
Shares Change (YoY)	+0.95%
Shares Change (QoQ)	+1.10%
Owned by Insiders (%)	9.23%
Owned by Institutions (%)	4.85%
Float	22.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	331.87
PB Ratio	152.66
P/TBV Ratio	168.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-74.76
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-156.12

Financial Position

The company has a current ratio of 0.57, with a Debt / Equity ratio of 0.69.

Current Ratio	0.57
Quick Ratio	0.34
Debt / Equity	0.69
Debt / EBITDA	n/a
Debt / FCF	-0.71
Interest Coverage	-10.71

Financial Efficiency

Return on equity (ROE) is -110.43% and return on invested capital (ROIC) is -144.73%.

Return on Equity (ROE)	-110.43%
Return on Assets (ROA)	-12.24%
Return on Invested Capital (ROIC)	-144.73%
Return on Capital Employed (ROCE)	-91.26%
Weighted Average Cost of Capital (WACC)	12.47%
Revenue Per Employee	439.42M
Profits Per Employee	-1.94B
Employee Count	18
Asset Turnover	0.09
Inventory Turnover	1.22

Taxes

Income Tax	-3.91B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +135.42% in the last 52 weeks. The beta is 1.50, so Mezzion Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.50
52-Week Price Change	+135.42%
50-Day Moving Average	123,594.00
200-Day Moving Average	75,071.50
Relative Strength Index (RSI)	38.76
Average Volume (20 Days)	725,481

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mezzion Pharma had revenue of KRW 7.91 billion and -34.93 billion in losses. Loss per share was -1,160.00.

Revenue	7.91B
Gross Profit	1.38B
Operating Income	-16.84B
Pretax Income	-38.84B
Net Income	-34.93B
EBITDA	-15.85B
EBIT	-16.84B
Loss Per Share	-1,160.00

Balance Sheet

The company has 25.57 billion in cash and 11.87 billion in debt, with a net cash position of 13.70 billion or 450.97 per share.

Cash & Cash Equivalents	25.57B
Total Debt	11.87B
Net Cash	13.70B
Net Cash Per Share	450.97
Equity (Book Value)	17.19B
Book Value Per Share	567.14
Working Capital	-33.99B

Cash Flow

In the last 12 months, operating cash flow was -16.59 billion and capital expenditures -137.39 million, giving a free cash flow of -16.73 billion.

Operating Cash Flow	-16.59B
Capital Expenditures	-137.39M
Depreciation & Amortization	988.12M
Net Borrowing	22.37B
Free Cash Flow	-16.73B
FCF Per Share	-550.52

Margins

Gross Margin	17.46%
Operating Margin	-212.91%
Pretax Margin	-491.02%
Profit Margin	n/a
EBITDA Margin	-200.42%
EBIT Margin	-212.91%
FCF Margin	n/a

Dividends & Yields

Mezzion Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.95%
Shareholder Yield	-0.95%
Earnings Yield	-1.33%
FCF Yield	-0.64%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.

Last Split Date	Apr 5, 2022
Split Type	Forward
Split Ratio	3

Scores

Mezzion Pharma has an Altman Z-Score of 6.86 and a Piotroski F-Score of 1.

Altman Z-Score	6.86
Piotroski F-Score	1